Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals with chronic HCV infection~* HCV RNA ≥10\^4 IU/mL at screening~* HCV genotypes 2, 3, 4, 5, or 6~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female~* Current or prior history of hepatic decompensation~* Hepatocellular carcinoma (HCC) or other clinically significant malignancy~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VOX+SOF/VEL 6 wk, TN, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
- GS-9857+SOF/VEL 6 wk, TN, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL 8 wk, TN, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL 8 wk,TE, without cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
- VOX+SOF/VEL 12 wk, TE, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
- GS-9857+SOF/VEL 8 wk, TE, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
- VOX+SOF/VEL 12 wk, TE, with cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)

Based on this trial design, predict the completion outcome and termination type (if applicable).